Streptococcus Patents (Class 424/93.44)
-
Patent number: 6908619Abstract: The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. CAMP factors can be used in vaccine compositions for the prevention and treatment of bacterial infections.Type: GrantFiled: January 21, 1999Date of Patent: June 21, 2005Assignee: University of SaskatchewanInventors: Min Jiang, Andrew A. Potter, Philip Ronald MacLachlan
-
Patent number: 6835818Abstract: This invention is directed to mutant SPE-C toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-C toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-C toxin. The mutant SPE-C toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-C toxin.Type: GrantFiled: July 14, 1999Date of Patent: December 28, 2004Assignee: Regents of the University of MinnesotaInventors: Patrick M. Schlievert, Douglas Ohlendorf, David T. Mitchell, Pamala J. Gahr
-
Patent number: 6773912Abstract: This invention provides an antibacterial protein, Salivaricin B. Salivaricin B is bacteriocidal with respect to, inter alia, S. pyogenes and therefore has numerous therapeutic applications. These applications include, but are not limited to, forming part of therapeutic formulations for use in treating or preventing streptococcal infections of the throat.Type: GrantFiled: December 21, 2001Date of Patent: August 10, 2004Assignees: University of Otago, Blis Technologies LimitedInventors: John Robert Tagg, Karen Patricia Dierksen, Mathew Upton
-
Patent number: 6774218Abstract: This invention is directed to mutant SPE-C toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-C toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-C toxin. The mutant SPE-C toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-C toxin.Type: GrantFiled: June 18, 1999Date of Patent: August 10, 2004Assignee: Regents of the University of MinnesotaInventors: Patrick M. Schlievert, Douglas Ohlendorf, David T. Mitchell, Pamela Gahr
-
Publication number: 20040105848Abstract: The present invention provides compositions and methods of using these compositions for enteric dialysis to treat renal, hepatic and gastrointestinal diseases by eliminating toxins and other metabolic waste products and reducing or retarding undesirable bacterial over growth. The compositions of the present invention comprise a probiotic. These compositions are useful in treating renal and hepatic diseases and bacterial overgrowth in the gastrointestinal tract.Type: ApplicationFiled: September 30, 2003Publication date: June 3, 2004Inventor: Natarajan Ranganathan
-
Patent number: 6716424Abstract: This invention provides a composition comprising a daidzein-containing substrate and a strain of micro-organism capable of metabolizing daidzein to equol as essential ingredients. This composition is effective in the prevention and alleviation of unidentified clinical syndrome inclusive of menopausal syndrome in middle-aged to elderly woman for which no effective means of prevention or alleviation has heretofore been available.Type: GrantFiled: February 8, 2000Date of Patent: April 6, 2004Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Shigeto Uchiyama, Tomomi Ueno, Megumi Kumemura, Kiyoko Imaizumi, Kyosuke Masaki, Seiichi Shimizu
-
Patent number: 6696057Abstract: A probiotic composition and method for the treatment of gastrointestinal disorders, hyperlipidemia and autoimmune diseases. The probiotic composition comprises a culture having lactobacillus bulgaricus and streptococcus thermophilus lactic acid bacteria and a carbohydrate enriched media, whereby the culture and media are combined and allowed to ferment until a desired ratio of the lactobacillus bulgaricus and streptococcus thermophilus organisms as well as a desired number of total organisms per dose are achieved. The method of the present invention comprises the steps of providing a probiotic composition of the present invention and administering the composition to a patient having at least one of gastrointestinal disorders, hyperlipidemia or autoimmune diseases.Type: GrantFiled: July 31, 2000Date of Patent: February 24, 2004Assignee: Lacpro Industries, Inc.Inventor: Gregory G. Bojrab
-
Patent number: 6682745Abstract: The present invention relates to the use of live attenuated bacteria for the manufacture of a vaccine for submucosal administration.Type: GrantFiled: January 27, 2000Date of Patent: January 27, 2004Inventors: Christiaan Antonius Arnoldus Jacobs, Danny Goovaerts
-
Patent number: 6663862Abstract: An isolated B1 domain polypeptide of bacterial Protein G which binds a Fab fragment of an IgG but substantially does not bind a Fc fragment of an IgG. Methods for the detection and purification of IgG Fc antibody fragments and Fab antibody fragments using the isolated GB1 domain polypeptides are also disclosed.Type: GrantFiled: June 4, 1999Date of Patent: December 16, 2003Assignee: Duke UniversityInventors: Homme W. Hellinga, David J. Sloan
-
Patent number: 6638516Abstract: The present invention relates to vaccine composition(s) comprising at least two PspAs from strains selected from at least one family, the family being defined by PspAs from strains belonging to the family having greater than or equal to 50% homology in aligned sequences of a C-terminal region of an alpha helical region of PspA. Additionally, the families are further comprised of clades, wherein PspAs from strains which belong to a clade exhibit at least 75% sequence homology in aligned sequences of the C-terminal region of the alpha helix of PspA. Vaccine compositions of the present invention preferably comprise a minimum of 4 and a maximum of 6 strains representing a single clade each, and the at least two PspAs are optionally serologically or broadly cross-reactive.Type: GrantFiled: May 24, 1999Date of Patent: October 28, 2003Assignee: The UAB Research FoundationInventors: Robert S. Becker, David E. Briles, Susan Hollingshead
-
Publication number: 20030180271Abstract: The present invention relates to microorganisms for the treatment or the prevention of obesity or diabetes mellitus, which reduce the amount of monosaccharide or disaccharide which may be absorbed into human body by converting monosaccharides such as glucose, fructose, galactose et al. and disaccharides into polymeric materials which cannot be absorbed by the intestine, and relates to a pharmaceutical composition containing the said microorganisms.Type: ApplicationFiled: February 3, 2003Publication date: September 25, 2003Applicant: BIONEER CORPORATIONInventors: Han Oh Park, Young Bae Bang, Hea Jung Joung, Bong Cheol Kim, Hang Rae Kim
-
Patent number: 6613549Abstract: The invention relates to probiotic microbes, including but not limited to Lactobacillus species and Bifidobacteria species, and their compositions and methods of employing said compositions for treating and preventing intestinal and other infections which originate from the intestine, in newborn infants. The invention also invention relates to the ability of probiotic organisms, either in viable or nonviable state, or their by-products, to interfere with pathogenic infection through short and long term colonization of the intestine, inhibition of growth of the pathogens, and assisting the host to fight off the infecting organisms.Type: GrantFiled: February 9, 2001Date of Patent: September 2, 2003Assignee: Urex Biotech, Inc.Inventors: Gregor Reid, Andrew W. Bruce, Victor Han
-
Novel strain of Streptomyces sp. and a process for the preparation of an alkaline protease inhibitor
Publication number: 20030138929Abstract: The present invention provides a novel strain of Streptomyces sp. having Accession Number PTA 973 and a process for the preparation of an alkaline protease inhibitor employing the said strain.Type: ApplicationFiled: February 3, 2003Publication date: July 24, 2003Applicant: Council for Scientific and Industrial Research (CSIR)Inventors: Jui Venkatesh Vernekar, Mohini Sadanand Ghatge, Mala Balchandra Rao, Vasanti Vishnu Deshpande -
Patent number: 6592876Abstract: PspAs, portions thereof, DNA therefor, and immunological compositions, primers and probes based thereon are disclosed claimed.Type: GrantFiled: September 15, 1995Date of Patent: July 15, 2003Assignee: UAB Research FoundationInventors: David E. Briles, Larry S. McDaniel, Edwin Swiatlo, Janet Yother, Alexis Brooks-Walter
-
Patent number: 6582695Abstract: The use of sphingomyelinase to increase the levels of skin and mucosal ceramides, as well as dermatological and cosmetic compositions containing same which are suitable for topical application are disclosed.Type: GrantFiled: May 22, 2001Date of Patent: June 24, 2003Assignee: VSL Pharmaceuticals Inc.Inventors: Renata Maria Anna Cavaliere Vesely, Claudio De Simone
-
Patent number: 6579711Abstract: Strain of lactic acid bacterium, (1) whose 16S ribosomal RNA is characteristic of the genus Streptococcus, (2) whose total protein profile, obtained after migration of the total proteins on an SDS-PAGE electrophoresis gel, is characteristic of that of the strain of lactic acid bacterium CNCM I-1920 but distinct from those of the recognized species belonging to the genus Streptococcus, namely S. acidominimus, S. agalactiae, S. alactolyticus, S. anginosus, S. bovis, S. canis, S. caprinus, S. constellatus, S. cricetus, S. cristatus, S. difficile, S. downei, S. dysgalactiae ssp. dysgalactiae, S. dysgalactiae ssp. equisimilis, S. equi, S. equi ssp. equi, S. equi ssp. zooepidemicus, S. equinus, S. ferus, S. gallolyticus, S. gordonii, S. hyointestinalis, S. hyovaginalis, S. iniae, S. intermedius, S. intestinalis, S. macacae, S. mitis, S. mutans, S. oralis, S. parasanguinis, S. parauberis, S. phocae, S. pleomorphus, S. pneumoniae, S. porcinus, S. pyogenes, S. ratti, S. salivarius, S. sanguinis, S. shiloi, S.Type: GrantFiled: April 13, 2000Date of Patent: June 17, 2003Assignee: Nestec S.A.Inventors: Walter Gaier, David Pridmore, Francesca Stingele, Jean-Richard Neeser, Patrice Desachy, Bruno Pot
-
Patent number: 6562336Abstract: This invention provides materials and procedures for the delivery of selected strains of bacteria and/or oxalate-degrading enzymes to the intestinal tracts of persons who are at increased risk for oxalate related disease because they have lost, or have inadequate concentrations of these bacteria. The administration of these bacteria and/or the relevant enzyme removes oxalate from the intestinal tract and thus reduces the amount of oxalate available for absorption and reduces the risk for oxalate related disease.Type: GrantFiled: November 26, 2001Date of Patent: May 13, 2003Assignee: VSL Pharma LimitedInventor: Claudio De Simone
-
Patent number: 6464981Abstract: A therapeutic agent for a cancer comprising a therapeutically effective amount of an active ingredient, wherein the therapeutic agent is used referring to an ability of acting on NK cell antigen receptor NKR-P1 of NKT cell as an index of the ability to activate the NKT cell.Type: GrantFiled: December 26, 2000Date of Patent: October 15, 2002Assignee: Orient Cancer Therapy Co., LTDInventor: Akikuni Yagita
-
Patent number: 6455063Abstract: A ruminant direct fed microbial composition of matter comprising an acidosis inhibiting effective amount of Propionibacterum P-63 is provided. Also disclosed is a process for reducing acidosis in ruminants or scours in swine by administration of the bacterium to the ruminant or swine. The microbial composition may be administered by itself, or combined with animal feed and/or lactic acid producing cultures.Type: GrantFiled: April 15, 1999Date of Patent: September 24, 2002Assignee: The Board of Regents for Oklahoma State UniversityInventors: Thomas Rehberger, Terry D. Parrott, Fred C. Owens, Charles A. Hibberd
-
Patent number: 6444203Abstract: A method of improving sleep in a mammal having a sleep disorder is disclosed. The method includes identifying the mammal having a sleep disorder and then administering Lactobacillus acidophilus CNCM I-2274, Lactobacillus acidophilus CNCM I-2132, Lactobacillus helveticus CNCM I-2275, Streptococcus thermophilus CNCM I-1520, Streptococcus thermophilus CNCM I-2272 or mixtures thereof. The method increases the length of the non rapid eye movement sleep phase and decreases the length of the rapid eye movement sleep phase. The bacteria can be administered in an orally consumable food product or a dietary supplement.Type: GrantFiled: December 20, 1999Date of Patent: September 3, 2002Assignee: Compagnie Gervais DanoneInventors: James M. Krueger, Michael J. Pabst, Chantal Cayuela, Marie-Christine Degivry, Donna Hartley
-
Patent number: 6428783Abstract: The invention concerns microbiology and medicine and may be used for the prophylaxis and treatment of the syndrome of an irritated large intestine in either a human or an animal. The insertion of the samples of the strains of the autochthonous bank into the intestine of a human permits the repair of the broken bacteriocenosis of the intestine due to the use of the entire spectrum of the healthy (normal) microflora of the intestine. The method is as follows: feces samples of a single human are taken during healthy periods beginning 7-15 days after birth and continuing through the course of a lifetime no more than once a year.Type: GrantFiled: March 11, 1998Date of Patent: August 6, 2002Assignee: Medtech Center, Inc.Inventors: Robert Khachatrian, Ashot Khachatrian
-
Patent number: 6423309Abstract: A processed food excellent for activating superoxidase dismutase is disclosed. The food contains 30 to 70% by weight of barley, wheat, rye or oats; 1 to 50% by weight of water soluble dietary fibers; 1 to 10% by weight of oligosaccharides; 0.5 to 5% by weight of powdered lactic acid bacteria and 5 to 15% by weight of powdered green tea. A method of making the food and a method for activating superoxide dismutase using the food is also disclosed.Type: GrantFiled: April 10, 2001Date of Patent: July 23, 2002Assignee: Toyo Shinyaku Co., Ltd.Inventors: Shinji Tsusaki, Kinya Takagaki
-
Patent number: 6403083Abstract: A pharmaceutical composition comprising activated hemicellulose (AHCC), a method for inducing IL-12 in a living body having tumor cells by administering the composition, and a method for treating cancer by administering the composition are provided.Type: GrantFiled: November 23, 1999Date of Patent: June 11, 2002Inventor: Akikuni Yagita
-
Publication number: 20020064522Abstract: A pharmaceutical composition comprising activated hemicellulose (AHCC), a method for inducing IL-12 in a living body having tumor cells by administering the composition, and a method for treating cancer by administering the composition are provided.Type: ApplicationFiled: December 3, 2001Publication date: May 30, 2002Inventor: Akikuni Yagita
-
Publication number: 20020061292Abstract: This invention provides materials and procedures for the delivery of selected strains of bacteria and/or oxalate-degrading enzymes to the intestinal tracts of persons who are at increased risk for oxalate related disease because they have lost, or have inadequate concentrations of these bacteria. The administration of these bacteria and/or the relevant enzyme removes oxalate from the intestinal tract and thus reduces the amount of oxalate available for absorption and reduces the risk for oxalate related disease.Type: ApplicationFiled: November 26, 2001Publication date: May 23, 2002Inventor: Claudio De Simone
-
Patent number: 6379677Abstract: Safe and effective mono and polyvalent vaccines against Streptococcus iniae may be prepared from formalin-killed cells and concentrated extracellular products of Streptococcus iniae which include one or more of deposited strains NRRL B-30238 and NRRL B-30242. Intraperitoneal and intramuscular vaccination of tilapia show acquisition of effective immunity against homologous and heterologous isolates of S. iniae.Type: GrantFiled: February 25, 2000Date of Patent: April 30, 2002Assignee: The United States of America as represented by the Secretary of the Department of AgricultureInventors: Phillip H. Klesius, Craig A. Shoemaker, Joyce J. Evans
-
Patent number: 6368591Abstract: This invention provides a microbe composition comprising three viable and beneficial lactic acid producing bacteria of new strains: Bifidobacterium longum 6-1 (CCTCC Number M 98003), Lactobacillus acidophilus YIT 2004 (CCTCC Number M 98004) and Sterptococcus faecalis YIT 0027 (CCTCC Number M 98005). This invention also provides the materials to protect the viability of the lactic acid producing bacteria in lyophilized form and the method to prepare the composition. Finally, this invention provides various uses of the composition.Type: GrantFiled: May 15, 1998Date of Patent: April 9, 2002Assignee: Shanghai SINE Pharmaceutical Corporation Ltd.Inventors: Bin Hua Chen, Yi Qiang Yao
-
Publication number: 20020025309Abstract: A stable fixed dose oral pharmaceutical formulation is provided. The formulation contains at least one anti-infective agent and at least one susceptible microorganism as active ingredients. At least one of the active ingredients is coated to provide a protective barrier around the active ingredient, the active ingredients being contained in a single pharmaceutical formulation. The formulation may be a tablet, a capsule, or a powder which may be made into a stable liquid. The protective barrier protectis the susceptible micro-organism from the effect of the anti-infective agent to maintain the susceptible micro-organism in a viable form for a period of at least three months. The anti-infective agent can be an antibiotic such as an amoxycillin and the microorganism can be Lactobacillus acidophilus.Type: ApplicationFiled: August 23, 2001Publication date: February 28, 2002Applicant: Cadila Pharmaceuticals Ltd.Inventors: Rajiv Indravadan Modi, Yatish Kumar Bansal, Bakulesh Mafatlal Khamar
-
Patent number: 6326000Abstract: Enteral compositions containing Streptococcus thermophilus, Bifidobacterium infantis and Bifidobacterium longum, each at a concentration equal to or greater than 1×1011 CFU per gram, are useful as adjuncts for enteral formulations and as oral nutritional supplements. The compositions can be administered before, during or at the end of an enteral formulation administration. The compositions can be administered separately or mixed with the enteral formulation. The compositions can also be employed at the end of the daily administration in order to prevent the colonization of the enteral tube by the other pathogens. The compositions can also be used as supplement to any liquid, creamy or pasty foodstuff. The present invention relates to a kit comprising two containers, one containing a foodstuff and the other containing the enteral composition consisting of Streptococcus thermophilus, Bifidobacterium infantis and Bifidobacterium longum.Type: GrantFiled: March 15, 2000Date of Patent: December 4, 2001Inventors: Renata Maria Anna Cavaliere ved. Vesely, Claudio De Simone
-
Patent number: 6319895Abstract: Lactoferrin tablets comprising as the active ingredients lactoferrin and lactulose and having a horizontal hardness of at least 4 kg and a vertical hardness of at least 3 kg; and lactoferrin tablets comprising as the active ingredients a microbial cell powder of at least one microorganism selected from among lactic acid bacteria, lactoferrin and lactulose and having a horizontal hardness of at least 4 kg and a vertical hardness of at least 3 kg. These tablets can be produced by using the conventional tableting apparatuses and yet have high hardness. Thus, they do not adhere to the inner wall of the oral cavity and have a favorable taste. Since no excessive tableting pressure is needed in the production process, moreover, these tablets can contain much viable cells of lactic acid bacteria, though they are in the form of rigid tablet.Type: GrantFiled: September 2, 1999Date of Patent: November 20, 2001Assignee: Morinaga Milk Industry Co., Ltd.Inventors: Mamoru Tomita, Ryo Kato, Yuzo Asano, Kenji Nishi, Yuriko Iiyama, Tsutomu Kudo
-
Patent number: 6312955Abstract: The present invention features gram-positive bacteria resistant to 5-fluorodeoxyuridine (FUdR). Such bacteria will preferably be commensal, and will not be resistant to antibiotics. Bacteria according to the present invention may also be transformed with DNA encoding an antigenic protein. Such transformed bacteria may be used to formulate a vaccine, in order to stimulate an immune response to the antigenic protein in a patient. The present invention further provides a method for isolating gram-positive bacteria resistant to FUdR.Type: GrantFiled: April 29, 1999Date of Patent: November 6, 2001Assignee: Siga PharmaceuticalsInventors: Dennis E. Hruby, Christine A. Franke
-
Patent number: 6306391Abstract: A process of making a stable fixed dose oral pharmaceutical formulation is provided. The formulation contains at least one anti-infective agent and at least one microorganism. The process involves a step of first coating the agent and/or the microorganism to provide a protective barrier around it. Next, the process involves a step of combining the agent and the microorganism into a single pharmaceutical formulation in the form of a capsule or a tablet. The barrier protects the microorganism from the effect of the anti-infective agent to maintain the microorganism in a viable form for a period of at least three months. The agent can be an antibiotic such as amoxycillin and the microorganism can be Lactobacillus acidophilus.Type: GrantFiled: March 23, 1998Date of Patent: October 23, 2001Assignee: Cadila Pharmaceuticals, Ltd.Inventors: Rajiv Indravadan Modi, Yatish Kumar Bansal, Bakulesh Mafatlal Khamar
-
Patent number: 6287555Abstract: The present invention is directed to a method of preventing the over-production of acid in an animal comprising administering to the animal a vaccine including an acid producing microorganism and/or antigenic fragment or fragments thereof effective to prevent the over-production of acid in the animal. The vaccine includes lactic acid producing microorganisms obtainable from the normal gut flora of an animal. In particular the vaccine includes Streptococcus bovis and/or Lactobacillus spp.Type: GrantFiled: May 13, 1998Date of Patent: September 11, 2001Assignee: The University of New EnglandInventors: Harsharnjit Singh Gill, Ronald Alfred Leng, Quan Shu
-
Publication number: 20010006671Abstract: Suspensions, emulsions or dispersions of therapeutically active agents which are water insoluble or water intolerant such as nutritional supplements, herbal products, drugs, bacteria, yeast, vitamins and minerals are prepared as suspensions in edible vegetable oils such as orange, lemon, soybean, cotton seed, peanut, canola corn oil, sunflower, safflower, palm kernel, palm and coconut. The active therapeutic agent may be in crystalline or amorphous form, it may be a liquid as for example an oil such as vitamin E or beta carotene, or a preparation of a comminuted plant structure such as flower, parts, leaf, stem, root or tree bark, or an extract of a dried plant structure, or a freeze dried preparation of a vital bacteria or yeast. The suspension is formed by active mixing of the active agent and oil.Type: ApplicationFiled: January 3, 2000Publication date: July 5, 2001Inventors: LOUIS P. GOODMAN, DENNIS BIZUB
-
Patent number: 6238660Abstract: A pharmaceutical composition comprising activated hemicellulose (AHCC), a method for inducing IL-12 in a living body having tumor cells by administering the composition, and a method for treating cancer by administering the composition are provided.Type: GrantFiled: November 12, 1997Date of Patent: May 29, 2001Inventor: Akikuni Yagita